Quince Therapeutics Files 8-K
Ticker: QNCX · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jul 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, regulation-fd, financial-reporting
TL;DR
Quince Therapeutics (fka Cortexyme) filed an 8-K on 7/16/25. Standard update.
AI Summary
Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed an 8-K on July 16, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The company, incorporated in Delaware, is based in South San Francisco, California, and operates in the biological products sector.
Why It Matters
This filing provides an official update on Quince Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates without introducing new, immediate risks.
Key Numbers
- 001-38890 — SEC File Number (Identifies the company's filing with the SEC)
- 90-1024039 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- Cortexyme, Inc. (company) — Former company name
- July 16, 2025 (date) — Date of earliest event reported
- South San Francisco, California (location) — Principal executive offices location
- Delaware (location) — State of incorporation
FAQ
What specific events are detailed in the Regulation FD Disclosure section of this 8-K?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.
What is the primary business of Quince Therapeutics, Inc.?
Quince Therapeutics, Inc. operates in the sector of Biological Products (No Diagnostic Substances), SIC code 2836.
When did the company change its name from Cortexyme, Inc.?
The company's name was changed from Cortexyme, Inc. on January 4, 2016.
What is the physical address of Quince Therapeutics' principal executive offices?
The principal executive offices are located at 601 Gateway Boulevard, Suite 1250, South San Francisco, California, 94080.
What is the fiscal year end for Quince Therapeutics, Inc.?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Quince Therapeutics, Inc. (QNCX).